Tarsus Pharmaceuticals (TARS) Profit After Tax (2019 - 2026)

Tarsus Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 69.68% year-over-year to -$7.6 million in Q1 2026; TTM through Mar 2026 was -$48.5 million, a 53.75% increase from a year earlier, with the FY2025 full-year figure at -$66.2 million, up 42.61% from the prior year.
• Profit After Tax rose to -$7.6 million in Q1 2026 per TARS's latest filing, from -$8.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$5.7 million in Q2 2022 and bottomed at -$41.8 million in Q4 2023.
• The 5-year median for Profit After Tax is -$22.9 million (2024), against an average of -$22.8 million.
• Across the five-year window, Profit After Tax slumped 447.17% in 2023 and soared 69.68% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$13.7 million in 2022, then sank by 205.93% to -$41.8 million in 2023, then jumped by 45.18% to -$22.9 million in 2024, then soared by 64.37% to -$8.2 million in 2025, then advanced by 6.43% to -$7.6 million in 2026.
• Per Business Quant, the three latest TARS Profit After Tax figures stand at -$7.6 million (Q1 2026), -$8.2 million (Q4 2025), and -$12.3 million (Q3 2025).